HK1258235A1 - 在癌症治療中用於傳播病毒的PI3K P-δ110亞型抑制劑 - Google Patents

在癌症治療中用於傳播病毒的PI3K P-δ110亞型抑制劑

Info

Publication number
HK1258235A1
HK1258235A1 HK19100595.8A HK19100595A HK1258235A1 HK 1258235 A1 HK1258235 A1 HK 1258235A1 HK 19100595 A HK19100595 A HK 19100595A HK 1258235 A1 HK1258235 A1 HK 1258235A1
Authority
HK
Hong Kong
Prior art keywords
pi3k
viruses
delta
inhibitors
cancer
Prior art date
Application number
HK19100595.8A
Other languages
English (en)
Inventor
Yaohe Wang
Mark Ferguson
Nicholas R Lemoine
Original Assignee
Univ London Queen Mary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London Queen Mary filed Critical Univ London Queen Mary
Publication of HK1258235A1 publication Critical patent/HK1258235A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK19100595.8A 2016-01-11 2019-01-14 在癌症治療中用於傳播病毒的PI3K P-δ110亞型抑制劑 HK1258235A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662277002P 2016-01-11 2016-01-11
PCT/GB2017/050051 WO2017122000A1 (en) 2016-01-11 2017-01-11 Inhibitors of pi3k p-delta 110 for use in delivery of viruses in the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1258235A1 true HK1258235A1 (zh) 2019-11-08

Family

ID=57861179

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100595.8A HK1258235A1 (zh) 2016-01-11 2019-01-14 在癌症治療中用於傳播病毒的PI3K P-δ110亞型抑制劑

Country Status (10)

Country Link
US (1) US11351209B2 (zh)
EP (1) EP3402468B1 (zh)
CN (1) CN109219450A (zh)
ES (1) ES2959563T3 (zh)
HK (1) HK1258235A1 (zh)
HR (1) HRP20231299T1 (zh)
HU (1) HUE063428T2 (zh)
PL (1) PL3402468T3 (zh)
RS (1) RS64678B1 (zh)
WO (1) WO2017122000A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113368246B (zh) * 2021-05-12 2023-05-26 中山大学 一种增效的抗肿瘤药物
WO2022252044A1 (en) * 2021-05-31 2022-12-08 Suzhou Singleron Biotechnologies Co., Ltd. Drug repurposing to treat primary lung adenocarcinoma based on deep embeddings of single-cell sequencing analysis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019499B1 (ru) 2009-03-24 2014-04-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Производные атропоизомеров 2-пуринил-3-толилхиназолинона и способы применения
JP2013541945A (ja) * 2010-09-24 2013-11-21 オンコス セラピュティックス オサケ ユキチュア 腫瘍溶解性アデノウイルスベクターならびにそれに関連する方法および使用
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
CN103110939A (zh) 2012-10-23 2013-05-22 郑州大学 诱导肿瘤特异性免疫的疫苗及其应用
KR20210010958A (ko) 2012-11-08 2021-01-28 리젠 파마슈티컬스 소시에떼 아노님 Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
GB201405834D0 (en) 2014-04-01 2014-05-14 Univ London Queen Mary Oncolytic virus
US20190038713A1 (en) * 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer

Also Published As

Publication number Publication date
PL3402468T3 (pl) 2024-01-29
RS64678B1 (sr) 2023-11-30
CN109219450A (zh) 2019-01-15
HRP20231299T1 (hr) 2024-02-02
US20190022156A1 (en) 2019-01-24
ES2959563T3 (es) 2024-02-27
EP3402468B1 (en) 2023-07-26
EP3402468C0 (en) 2023-07-26
US11351209B2 (en) 2022-06-07
HUE063428T2 (hu) 2024-01-28
WO2017122000A1 (en) 2017-07-20
EP3402468A1 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
HK1249524A1 (zh) 用於治療血載癌症的免疫檢查點抑制劑
ZA201807810B (en) Adenosine derivatives for use in the treatment of cancer
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
IL258854A (en) Preparations containing cannabidiol and secondary medicinal agents for cancer treatment
IL266198A (en) Liposomal formulation for use in cancer treatment
IL276733A (en) Use of Aribolin in cancer treatment
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
IL247586A0 (en) Use of Aribolin and mtor inhibitors as a combined treatment for cancer
IL290251A (en) Combination for effective treatment of metastatic cancer in patients
PL3253208T3 (pl) Terapie kombinowane do zastosowania w leczeniu nowotworu piersi
EP3708173C0 (en) PHARMACEUTICAL COMPOSITION COMPRISING MIRNA-3140 FOR THE TREATMENT OF CANCER
HUE058749T2 (hu) Készítmények és módszerek homocisztinuria kezelésében történõ alkalmazásra
HK1258235A1 (zh) 在癌症治療中用於傳播病毒的PI3K P-δ110亞型抑制劑
EP3440052C0 (en) COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
IL253933A0 (en) History of pyrimidine use in the treatment of cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
HK1251476A1 (zh) 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment